Schrödinger Closes $85 Million Financing to Advance Computational Platform and Expand Drug Discovery Pipeline
Investment in R&D will extend capabilities of computational platform and support growth of partnered and proprietary programs
NEW YORK--(BUSINESS WIRE)--Schrödinger, a privately held company revolutionizing drug discovery through advanced molecular simulations, today announced the closing of an $85 million financing to support continued growth and innovation of its computational platform and expansion of its drug discovery pipeline.
The Bill and Melinda Gates Foundation Trust and WuXi AppTec’s Corporate Venture Fund co-led the round, joined by leading life science and tech investors Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures).
“Schrödinger has demonstrated that precise molecular design can significantly accelerate drug discovery and lead to unexpected solutions that stand to benefit patients. We’re pleased to support this exciting stage in Schrödinger’s growth,” said Bill Gates, who has led three previous investments in Schrödinger since 2010.
The new investment will support Schrödinger’s ongoing research and development to extend the capabilities of its widely adopted computational platform for drug discovery and materials research. The company also plans to add scientists and developers and expand its drug discovery team to work on a growing pipeline of assets. Schrödinger’s pipeline spans both partnered and proprietary programs for a range of indications, including several compounds in clinical development.
“We continue to be impressed by Schrödinger’s ability to drive in an innovative way the development of new medicines,” said Dr. Ge Li, Chairman of WuXi Group and CEO of WuXi AppTec. “We look forward to the accelerated progress this investment will bring for patients who are counting on our industry to deliver medicines and treatments for critical, unmet medical needs.”
“The investment will allow us to continue to advance our technology platform to help our users accelerate their work in life sciences and materials design. We are also excited to expand our drug discovery efforts, leveraging our platform to grow our pipeline and discover new medicines more efficiently,” said Ramy Farid, Ph.D., Schrödinger’s CEO. “Our growth will help us realize our mission to improve human health and quality of life.”
About Schrödinger
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Schrödinger has a growing pipeline of early-stage assets and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. In addition, the company has deep partnerships and collaborations in such fields as biotechnology, pharmaceuticals, chemicals, and electronics. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Founded in 1990, Schrödinger has nearly 400 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.
As drug manufacturers speed up their efforts to find a new treatment drug for the coronavirus outbreak that has devastated China and has caused a world-wide panic, a Chinese drug company mid February announced that it has started mass-producing an experimental drug from Gilead Sciences that has the potential to fight the novel coronavirus (1).
BrightGene Bio-Medical Technology, a Suzhou based company (2), just announced that it has developed the technology to synthesize the active pharmaceutical ingredients of Remdesivir, the drug developed by Gilead Biosciences. Its stock price surged 20% in Tuesday morning trading in Shanghai (1).
“While BrightGene said that it intends to license the drug from Gilead, its move to start manufacturing at this early stage is highly unusual and a potential infringement of the American company’s intellectual property.“(1) This comes a week after Chinese researchers at the Wuhan Institute of Virology filed an application to patent Gilead’s drug Remdesivir to treat the new coronavirus, a bid that would give China leverage over the global use of the therapy to fight the outbreak (1)(3)(4).
The decision to seek a patent instead of invoking a “compulsory license” option that lets nations override drug patents in national emergencies, signals China’s commitment toward intellectual property rights. The timing is uncanny! Right? Gilead will retain the global rights to market the antiviral medication, once approved (3). Gilead has also announced that it is partnering with the Chinese Health Authorities on the clinical trials of Remdesivir as a treatment for coronavirus (5). Remdesivir was originally developed in 2016 by Gilead as a treatment for the Ebola virus (13). Many have argued that China stole the patent from Gilead due to a technicality, but you will soon see that this is indeed not the case (14).
And who exactly is Gilead Biosciences? Gilead is partnered with Wuxi Pharmaceuticals (Wuxi AppTec) owned by New World Order philanthropist and mass manipulator himself, George Soros (6)(7)! Here is a printout of Soros Fund Managaement Portfolio which will confirm this (8)!
Wuxi Pharmaceuticals is conveniently located in the epicenter of the outbreak near Wuhan Institute of Virology that has been implicated as the Bioweapons manufacturer of this coronavirus (10)(11)(12)! Looks like China has both the Bioweapon and the cure! And let’s not forget the patent on the treatment drug! How charitable do you suppose China will be with the west?
But this story doesn’t end here. George Soros also owns Gilead Biosciences (15).
According to The Gateway Pundit, doctors at Providence Regional Medical Center successfully treated a coronavirus patient within hours using Gilead’s drug Remdesivir (16). Given the current outbreak that has taken the world by surprise, it’s important to look at all the current players. How is Gilead Biosciences tied to this viral outbreak?
Gilead endorsed and is involved in a drug purchasing group called UNITAID whose mandate is to create a “patent pool” for pharmaceutical companies to share their “drug patents” with other companies in order to produce generic drugs for distribution to poor African nations (17)(18). The royalties from the sales of these generic drugs are then paid to the patent holders. payable to the patent holders (19). UNITAID emerged from the United Nations 2000 Millennium Declaration, which has now evolved into the UN Global Compact (20)(21). Their internet timeline shows that the UNITAID website Unitaid.org is also linked to Refunite.org an agency partnered with the UN Refugee Agency UNHCR that helps to connect refugees with their families using the internet (22)(23)(24)(25)(26).
UNITAID has several financial backers including: WHO, UNAIDS, Global Fund, and the Roll Back Malaria Partnership. In addition, UNITAID has corporate sponsorship from pharmaceuticals with the “Medicines Patent Pool” (28).
One billionaire investor behind UNITAID is George Soros himself (29). But why stop there? UNITAID is also financed by the Bill and Melinda Gates Foundation and also involves a partnership with the Clinton Health Access Initiative (CHAI) (30)(31). And interestingly enough both UNITAID and Gilead Biosciences supported Hillary Clinton for president in 2016 (32)(33).
UNITAID’s objectives are to exclude high and middle-income countries from “drug pool” while allowing “developing” countries to benefit from lower drug prices (35). In 2009 UNITAID’s board voted to exclude China and other more lucrative nations when considering targeted nations outside of Africa. However, since then all that has changed and UNITAID has now included China in its “drug pool” (36).
Minutes of the Executive Board of UNITAID dated December 5-6, 2018 in Marrakesh Morocco (which coincided with the signing of the UN Global Compact on Migration) stated the following (37)(38):
THE REPRESENTATIVE OF WHO INFORMED THE BOARD OF A RECENT MEETING COORDINATED BY WHO WITH SEVERAL GLOBAL HEALTH PARTNERS (GPEI, GFF, GAVI, UNITAID, GLOBAL FUND) TO SUPPORT THE DEVELOPMENT OF A COMMON HEALTH NARRATIVE. WITH REGARD TO PARLIAMENTARY ENGAGEMENT, HE INFORMED OF A NEW MEMORANDUM OF UNDERSTANDING (MOU) BETWEEN WHO AND THE INTER-PARLIAMENTARY UNION AND ENCOURAGED UNITAID TO BUILD ON THIS COMMITMENT IN ITS COUNTRY WORK. HE UNDERLINED THE IMPORTANT ROLE OF BOARD MEMBERS IN SUPPORTING THE UNITAID SECRETARIAT BY OPENING NEW DOORS AND LEVERAGING EXISTING POLITICAL AND OTHER CONNECTIONS. HE ALSO GAVE POSITIVE FEEDBACK ON THE RECENT UNITAID-WHO VISIT TO CHINA, WHICH EXPLORED OPPORTUNITIES FOR ENGAGEMENT.
A year later we now have a Global Pandemic emerging from Mainland China and the Chinese are the holders of the patent for the treatment drug and they are also included in the United Nation’s UNITAID initiative that will see them benefit with lower drug pricing. Furthermore Gilead, a main supporter of UNITAID (39), has also announced that it is partnering with the Chinese Health Authorities on the clinical trials of Remdesivir as a treatment for coronavirus (5). And once approved, Gilead will retain the global rights to market the antiviral medication (3).
UNITAID is the UN and this is bio-warfare, where they control the drugs. China did not steal Gilead’s patent; Gilead was a willing participant, they are even working with the Chinese government on clinical trials. The question remains, how will this impact western nations that are excluded from the acquisition of lower-priced treatment drugs? Will our economies be held hostage to Chinese imperialism? And has the coronavirus outbreak been the vehicle for George Soros, Bill Gates, and the United Nations to implement the New World Order? It sure look’s like it! Checkmate!
(210 bytes)
()
05/26/2020 postreply
23:54:26
